Cocrystal Pharma Inc (COCP)
NASDAQ:COCP
Want to see COCP full AI Analyst Report?
Top Page
Cocrystal Pharma
(NASDAQ:COCP)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.00
▼(-8.26% Downside)
Action:Reiterated
Date:06/04/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses and cash burn, and a sharply reduced equity base that increases funding risk). Technicals also remain bearish with the stock below key moving averages and negative MACD, despite oversold readings. Positive corporate developments (Fast Track designation and clinical progress) provide support but are not sufficient to offset the current financial and trend risks, while valuation metrics offer limited help due to negative earnings and no dividend yield data.
Positive Factors
FDA Fast Track for CDI-988
Fast Track designation for CDI-988 establishes a durable regulatory advantage: it enables closer FDA interaction, rolling reviews and potential expedited timelines. That structurally reduces regulatory risk, enhances partner interest and can shorten development-to-market timelines if clinical data are favorable.
Negative Factors
No commercial revenue
The absence of operating revenue leaves the business dependent on financing and milestone deals. Persistent TTM net losses around $8.8M mean runway and program continuity hinge on external capital or partnerships, raising structural dilution and execution risk until commercialization or significant licensing occurs.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA Fast Track for CDI-988
Fast Track designation for CDI-988 establishes a durable regulatory advantage: it enables closer FDA interaction, rolling reviews and potential expedited timelines. That structurally reduces regulatory risk, enhances partner interest and can shorten development-to-market timelines if clinical data are favorable.
Read all positive factors
Cocrystal Pharma (COCP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.30M
Dividend YieldN/A
Average Volume (3M)3.12M
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth53.06%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding13,787,453
10 Day Avg. Volume178,720
30 Day Avg. Volume3,115,767
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue36.53
Enterprise Value/Gross Profit5.45
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$10.00Price Target Upside817.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Cocrystal Pharma Business Overview & Revenue Model
Company Description
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to...
How the Company Makes Money
Cocrystal Pharma does not have publicly disclosed, consistent revenue from commercial product sales because it is a clinical-stage company and, to the extent publicly available information indicates, it does not market FDA-approved products. As a ...
Cocrystal Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -12.54M | -15.17M | -12.39M | -8.79M |
| EBITDA | -8.64M | -17.75M | -20.97M | -17.95M | -14.03M |
| Net Income | -8.83M | -17.50M | -17.98M | -38.84M | -14.19M |
Balance Sheet | |||||
| Total Assets | 9.71M | 13.46M | 31.26M | 40.84M | 79.39M |
| Cash, Cash Equivalents and Short-Term Investments | 7.03M | 9.86M | 26.35M | 37.14M | 58.70M |
| Total Debt | 1.50M | 1.81M | 1.85M | 297.00K | 534.00K |
| Total Liabilities | 3.38M | 3.93M | 4.88M | 1.27M | 1.84M |
| Stockholders Equity | 6.33M | 9.52M | 26.38M | 39.57M | 77.55M |
Cash Flow | |||||
| Free Cash Flow | -8.20M | -16.49M | -14.78M | -21.51M | -12.77M |
| Operating Cash Flow | -8.19M | -16.48M | -14.67M | -21.43M | -12.72M |
| Investing Cash Flow | -12.00K | -8.00K | -118.00K | -74.00K | -52.00K |
| Financing Cash Flow | 5.37M | 0.00 | 3.99M | -27.00K | 38.47M |
Cocrystal Pharma Technical Analysis
Negative
1.09
Price Trends
1.28
Negative
1.15
Negative
1.16
Negative
Market Momentum
-0.08
Positive
26.38
Positive
6.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCP, the sentiment is Negative. The current price of 1.09 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.28, and below the 200-day MA of 1.16, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 26.38 is Positive, neither overbought nor oversold. The STOCH value of 6.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COCP.
Cocrystal Pharma Risk Analysis
Cocrystal Pharma disclosed 53 risk factors in its most recent earnings report. Cocrystal Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cocrystal Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $20.70M | -0.53 | -248.91% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $10.32M | -0.33 | -423.84% | ― | -8.47% | 25.61% | |
44 Neutral | $9.69M | -2.48 | -49.00% | ― | 11.90% | 43.46% | |
43 Neutral | $13.30M | -1.51 | -94.94% | ― | ― | 53.06% | |
| ― | $12.07M | -0.61 | -94.79% | ― | ― | 79.70% | |
43 Neutral | $19.66M | -0.10 | -83.59% | ― | ― | 19.36% |
* Healthcare Sector Average
COCP
Cocrystal Pharma
0.96
-0.69
-41.58%
CLRB
Cellectar Biosciences
2.59
-8.06
-75.68%
IMRN
Immuron
1.25
-0.44
-26.04%
BRTX
BioRestorative Therapies
0.41
-1.41
-77.62%
BIVI
BioVie
1.60
-9.60
-85.71%
SNSE
Sensei Biotherapeutics
14.65
7.67
109.83%
Cocrystal Pharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Cocrystal Pharma Names New CEO to Drive Antiviral Pipeline
Positive
Jun 3, 2026
Cocrystal Pharma has appointed biopharma executive James Sapirstein as Chief Executive Officer, effective June 3, 2026, as the company advances multiple clinical antiviral programs built on its structure-based drug discovery platform. He succeeds ...
Business Operations and StrategyProduct-Related Announcements
Cocrystal Pharma Reports Promising Pan-Viral Antiviral Activity
Positive
May 26, 2026
On May 26, 2026, Cocrystal Pharma announced that its novel direct-acting antiviral molecules have shown pan-viral activity in vitro against multiple pathogens, including hantaviruses, bunyaviruses and influenza viruses, by targeting a highly conse...
Business Operations and StrategyProduct-Related Announcements
Cocrystal Showcases Norovirus Candidate CDI-988 at ICAR 2026
Positive
Apr 30, 2026
On April 30, 2026, Cocrystal Pharma announced that its first oral protease inhibitor CDI-988 for norovirus prevention and treatment was highlighted in an oral presentation at the 39th International Conference on Antiviral Research in Prague, under...
Business Operations and StrategyRegulatory Filings and Compliance
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug
Positive
Apr 2, 2026
On April 2, 2026, Cocrystal Pharma announced that the U.S. Food and Drug Administration granted Fast Track designation to CDI-988, its oral, direct-acting protease inhibitor and the first known oral antiviral candidate being developed for both tre...
Executive/Board Changes
Cocrystal Pharma Announces Passing of Board Member Japour
Negative
Mar 13, 2026
On March 10, 2026, Cocrystal Pharma, Inc. announced the passing of board member Dr. Anthony Japour, marking a significant loss for the company’s leadership. His death removes an experienced figure from the board, creating a gap in governance...
Business Operations and StrategyProduct-Related Announcements
Cocrystal Initiates Phase 1b Norovirus Antiviral Challenge Study
Positive
Mar 9, 2026
On March 9, 2026, Cocrystal Pharma reported that the first subjects were dosed in a Phase 1b norovirus human challenge study at Emory University School of Medicine, evaluating its oral antiviral CDI-988 as both a preventive and treatment for norov...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.